Evicenter
P&T meetings

Imlifidase

Kidney transplantation in highly sensitized patients

Manufacturer
Hansa Biopharma
Regulatory submission
BLA submitted December 2025
Last updated
85 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

2 evidence topics · 2 sources

Product information: pharmacokinetic parameters
ParameterQuoted value
Mean maximum concentration after 0.25 mg/kg“5.8 (4.2‑8.9) µg/mL”
Mean distribution half-life“1.8 (0.6‑3.6) hours”
Mean elimination half-life“89 (60‑238) hours”
Mean clearance“1.8 (0.6‑7.9) mL/h/kg”
Mean distribution volume during elimination“0.20 (0.06‑0.55) L/kg”